P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Fax (435) 755-0015 - www.scytek.com

Super Block

Description: Super Block has been developed to use with immunolabeling techniques for the reduction of nonspecific background staining, and simultaneously reducing the handling of animal serums in the laboratory. The need to match species with the secondary antibody is eliminated due to the lack of normal serum in this product. Super Block has been shown to be effective for immunohistochemical, ELISA, blot and In-situ techniques and requires no mixing or diluting.

pH: 7.4±0.1

Uses/Limitations:
Not to be taken internally.
For In-Vitro Diagnostic use only.
Histological applications.
Do not use if reagent becomes cloudy.
Do not use past expiration date.
Use caution when handling reagent.
Non-Sterile.

Control Tissue: Any well-fixed tissue.

Availability:

Item #	Volume
AAA125	125 ml
AAA500	500 ml
AAA999	1000 ml
AAA010	10 L
AAA-20000	20 L
AAA-50000	50 L
AAA-100000	100 L



Human Thyroid stained with a TTF-1 antibody within an IHC procedure. Super Block was used to prevent nonspecific background staining.

Storage: Store Super Block at 2-8°C. Product is stable for 18 months from date of manufacture.

Procedure:

Immunohistochemical:

1. Incubate tissue section for 5 minutes at either room temperature or 37° C prior to application of the primary antibody. After incubation, rinse once in buffer (Note: do not incubate tissue sections in excess of 10 minutes or a reduction in desired staining may occur).

2. *** For bulk staining, pour Super Block in a covered staining tray and dip slides for 5 minutes. Replace with fresh Super Block after 5-10 uses. This step can be performed at the time of deparaffinization is desired. ***

Storage: 2° C 8° C

ScyTek Laboratories, Inc.
205 South 600 West
Logan, UT 84321
435-755-9848
U.S.A.

CE IVD

EC REP
Emergo Europe
Prinsessegracht 20
2514 AP The Hague, The Netherlands

3. For antibodies with particularly high background staining, dilute Super Block in PBS (1:5-10) and use as a wash buffer in addition to the blocking step.

ELISA:

1. Incubate microtiter well for 2-10 minutes prior to addition of sample. Rinse, and continue procedure. (Note: do not incubate in excess of 10 minutes).

Chemiluminescent Blot

1. It has been reported to ScyTek, that Super Block is effective for this technique with incubation times of one hour at room temperature. It has also been reported that Super Block is an effective blocker when used with overnight incubations at 2-8° centigrade.

Precautions: Do not pipette reagent by mouth.
Avoid contact with skin and eyes.
Wash after use.
Observe all federal, state and local environmental regulations regarding disposal.

Product Specific Literature References:

1) Buttini M., Yu G.Q., Shockley K., Huang Y., et al. Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform, Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation. The Journal of Neuroscience, Vol. 22, No. 24, pp 10539-10548, December 15, 2002.

2) Evans C.F., Horwitz M.S., Hobbs M.V., Oldstone M. Viral Infection of Transgenic Mice Expressing a Viral Protein in Oligodendrocytes Leads to Chronic Central Nervous System Autoimmune Disease. Journal of Experimental Medicine, Vol. 184 pp 2371-2384, December 1996.

3) Goleva E., Kisich K.O., Leung D.Y.M. A Role for STAT5 in the Pathogenesis of IL-2-Induced Glucocorticoid Resistance. The Journal of Immunology, Vol. 169, pp 5934-5940, 2000.

4) Lee E.H., Seomun Y., Hwang K.H., Kim J.E., Kim I.S., Kim J.H., Joo C.K. Overexpression of the Transforming Growth Factor-β-Inducible Gene βig-h3 in Anterior Polar Cataracts. Investigational Ophthalmology & Visual Science, Vol. 41, No. 7, pp 1840-1845, June 2000.

5) Lemaitre V., O'Byrne T.K., Borczuk A.C., et al. ApoE Knockout Mice Expressing Human Matrix Metalloproteinase-1 in Macrophages have less Advanced Atherosclerosis. The Journal of Clinical Investigation, Vol. 107, No. 10, pp 1227-1234, May 2001.

6) Matsubara S., Wada Y., Gardner T.A., et al. A Conditional Replication-competent Adenoviral Vector, Ad-OC-E1a, to Cotarget Prostate Cancer and Bone Stroma in an Experimental Model of Androgen-independent Prostate Cancer Bone Metastasis. Cancer Research, Vol. 61, pp 6012-6019, August 15, 2001.

7) Pauley R.J., Santner S.J., Tait L.R., Bright R.K., Stanten R.J. Regulated CYP19 Aromatase Transcription in Breast Stromal Fibroblasts. The Journal of Clinical Endocrinology & Metabolism, Vol. 85, No. 2, pp 837-846, 2000.

8) Nemeth J.A., Yousif R., Herzog M., et al. Matrix Metalloproteinase Activity, Bone Matrix Turnover, and Tumor Cell Proliferation in Prostate Cancer Bone Metastasis. Journal of the National Cancer Institute, Vol. 94, No. 1, pp 17-25, January 2, 2002.

9) Nemeth J.A., Harb J.F., Barroso U., et al. Severe Combined Immunodeficient-hu Model of Human Prostate Cancer Metastasis to Human Bone. Cancer Research, Vol. 59, pp 1987-1993, April 15, 1999.

Storage: 2° C  8° C


ScyTek Laboratories, Inc.
205 South 600 West
Logan, UT 84321
435-755-9848
U.S.A.

CE IVD

EC REP
Emergo Europe
Prinsessegracht 20
2514 AP The Hague, The Netherlands

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Fax (435) 755-0015 - www.scytek.com

10) Slominski A., Rologg B., Curry J., et al. The Skin Produces Urocortin. The Journal of Clinical Endocrinology & Metabolism, Vol. 85, No. 2, pp 815-823, 2000.

11) Tseng C.P., Ely B.D., Li Y., Pong R.C., Hsieh J.T., Regulation of Rat DOC-2 Gene During Castration-Induced Rat Ventral Prostate Degeneration and Its Growth Inhibitory Function in Human Prostatic Carcinoma Cells. Endocrinology, Vol. 139, No. 8, pp 3542-3553, 1998.

12) Tsunoda T., Inada H., Kalembeyi I., Imanaka-Yoshida K., et al. Involvement of Large Tenascin-C Splice Variants in Breast Cancer Progression. American Journal of Pathology, Vol. 162, No. 6, pp 1857-1867, June 2003.

13) Upadhyay J., Shekarriz B., Nemeth J.A., Dong Z., et al. Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) and MMP-2 Immunolocalization in Human Prostate: Change in Cellular Localization Associated with High-Grade Prostatic Intraepithelial Neoplasia. Clinical Cancer Research, Vol. 5. pp 4105-4110, December 1999.

14) Yamadori I., Yoshino T., Kondo E., Cao L., et al. Comparison of Two Methods of Staining Apoptotic Cells of Leukemia Cell Lines: Terminal Deoxynucleotidyl Transferase and DNA Polymerase I Reactions. The Journal of Histochemistry & Cytochemistry, Vol. 46, No. 1, pp 85-90, 1998.

15) Yasoda A., Ogawa Y., Suda M., Tamura N., et al. Natriuetic Peptide Regulation of Endochondral Ossification. The Journal of Biological Chemistry, Vol. 273, No. 19, pp 11695-11700, May 8, 1998.

16) Zhau H.Y.E., Chang S.M., Chen B.Q., Wang Y., et al. Androgen-repressed Phenotype in Human Prostate Cancer. Proc. National Academy of Science USA, Vol. 93, pp 15152-12157, Cell Biology, December 1996.

17) C. F. Evans, M. S. Horwitz, M. V. Hobbs, and M. B. Oldstone, "Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease," J. Exp. Med., vol. 184, no. 6, pp. 2371-2384, Dec. 1996.

18) G. N. Thalmann, P. E. Anezinis, S.-M. Chang, H. E. Zhau, E. E. Kim, V. L. Hopwood, S. Pathak, A. C. von Eschenbach, and L. W. K. Chung, "Androgen-independent Cancer Progression and Bone Metastasis in the LNCaP Model of Human Prostate Cancer," Cancer Res, vol. 54, no. 10, pp. 2577-2581, May 1994.

19) N. N. Shehadeh, F. LaRosa, and K. J. Lafferty, "Altered Cytokine Activity in Adjuvant Inhibition of Autoimmune Diabetes," Journal of Autoimmunity, vol. 6, no. 3, pp. 291-300, Jun. 1993.

Storage: 2° C 8° C

ScyTek Laboratories, Inc.
205 South 600 West
Logan, UT 84321
435-755-9848
U.S.A.

CE IVD

EC REP

Emergo Europe
Prinsessegracht 20
2514 AP The Hague, The Netherlands